Chronic Granulomatous Disease (CGD) is a rare genetic disorder that affects the immune system, specifically the ability of phagocytes to produce reactive oxygen species (ROS) necessary for ...

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

“Based on data from our preclinical studies, we believe PM359 has the potential to sufficiently correct a prevalent disease-causing mutation of CGD, leading to amelioration of disease for these ...